Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Apr 05, 2022 10:41pm
117 Views
Post# 34579041

RE:RE:RE:RE:Prothena

RE:RE:RE:RE:ProthenaUh...

Three Forms of Amyloid Protein

  • Monomers - Simple strings of amino acids that play a role in normal brain health.
  • Oligomers - Small clumps of molecules that consist of several monomer units.
  • Plaque - Insoluble, solid deposits of amyloid (similar to plaque in arteries) that can build up over time. Usually present, but does not appear to play a significant role in disease progression.

The Right Target

Only misfolded oligomers are toxic, which can lead to neuronal death and synaptic loss that causes AD-related cognitive decline. Studies indicate that safe and effective antibody therapies for AD will be those that selectively target and bind only to misfolded oligomers while avoiding any binding to monomers and/or plaque forms of amyloid.

https://www.promisneurosciences.com/product-pipeline/alzheimers-disease 

<< Previous
Bullboard Posts
Next >>